The role of mast cells and their proteases in lung damage associated with COVID-19

The new coronavirus infection COVID-19 (Coronavirus Disease 2019) caused by SARS-CoV-2, has posed scientific and public health challenges. The problem of treating COVID-19 still remains, and the pathogenesis of COVID-19 needs to be studied in detail, including the involvement of mast cells (MCs) and their specific proteases.

The aim of this study was to characterize the role of mast cell proteases chymase, tryptase, and carboxypeptidase A3 (CPA3) in the lung damage associated with COVID-19.

Methods. The study included postmortem lung biopsies from 30 patients who died of severe COVID-19, and biopsies from 9 control group patients. Histological preparations were made and protease profile and degranulation activity of MCs were analyzed. In addition, some demographic, clinical, and laboratory parameters were analyzed.

Results. The average number of tryptase-positive MCs without evidence of degranulation and the total number of CPA3-positive MCs were statistically significantly higher in patients with COVID-19, and the number of tryptase-positive and CPA3-positive MCs fragments was lower compared with controls. Negative correlations were established between the numbers of tryptase-positive MCs and red blood cell count. Negative correlations were found between non-granulating tryptase-positive MCs and hemoglobin levels. Positive correlations were noted between tryptase-positive MCs and the leukocytes and eosinophils counts, and negative correlations were noted between the number of CPA3-positive cells and the platelet count. A positive correlation was found between the number of adjoining MCs, as well as fragments of tryptase-positive MCs, and the erythrocyte sedimentation rate (ESR). A negative correlation was also observed between the number of non-degranulated CPA3-positive MCs and the blood level of C-reactive protein. In patients with COVID-19, reduced degranulation activity of tryptase-positive MCs was found along with increased representation of CPA3positive MCs. Several trends and associations with laboratory test results were noted. The potential involvement of MCs in the development of anemia and thrombocytopenia is considered. Associations were established between tryptase-positive MCs and the peripheral blood counts of leukocytes and eosinophils, as well as ESR.

Conclusion. The results obtained are highly contradictory. Since many aspects of the involvement of MCs and their proteases in COVID-19 pathogenesis are still unknown, studies with larger cohorts of patients are needed.

1. Ministry of Health of the Russian Federation. [The Temporary Guidelines: Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)]. Version 15 (February 22, 2022). Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/%D0%92%D0%9C%D0%A0_COVID-19_V15.pdf [Accessed: July 15, 2022] (in Russian).

2. Theoharides T.C. Potential association of mast cells with coronavirus disease 2019. Ann. Allergy Asthma Immunol. 2021; 126 (3): 217–218. DOI: 10.1016/j.anai.2020.11.003.

3. Afrin L.B., Weinstock L.B., Molderings G.J. COVID-19 hyperinflammation and post-COVID-19 illness may be rooted in MCs activation syndrome. Int. J. Infect. Dis. 2020; 100: 327–332. DOI: 10.1016/j.ijid.2020.09.016.

4. Krystel-Whittemore M., Dileepan K.N., Wood J.G. Mast cell: a multi-functional master cell. Front. Immunol. 2016; 6: 620. DOI: 10.3389/fimmu.2015.00620.

5. Atiakshin D.A., Shishkina V.V., Esaulenko D.I. et al. Mast cells as the target of the biological effects of molecular hydrogen in the specific tissue microenvironment. Int. J. Biomed. 2022; 12 (2): 183–187. DOI: 10.21103/Article12(2)_RA2.

6. Jing H., Liu L., Zhou J., Yao H. Inhibition of C-X-C motif chemokine 10 (CXCL10) protects mice from cigarette smoke-induced chronic obstructive pulmonary disease. Med. Sci. Monit. 2018; 24: 5748–5753. DOI: 10.12659/MSM.909864.

7. Budnevsky A.V., Ovsyannikov E.S., Shishkina V.V. et al. Possible unexplored aspects of COVID-19 pathogenesis: the role of Carboxypeptidase A3. Int. J. Biomed. 2022; 12 (2): 179–182. DOI: 10.21103/Article12(2)_RA1.

8. Nagashima S., Dutra A.A., Arantes M.P. et al. COVID-19 and lung mast cells: the kallikrein-kinin activation pathway. Int. J. Mol. Sci. 2022; 23 (3): 1714. DOI: 10.3390/ijms23031714.

9. Lam H.Y., Tergaonkar V., Kumar A.P., Ahn K.S. Mast cells: Therapeutic targets for COVID-19 and beyond. IUBMB Life. 2021; 73 (11): 1278–1292. DOI: 10.1002/iub.2552.

10. Elieh Ali Komi D., Wöhrl S., Bielory L. Mast cell biology at molecular level: a comprehensive review. Clin. Rev. Allergy Immunol. 2020; 58 (3): 342–365. DOI: 10.1007/s12016-019-08769-2.

11. Kempuraj D., Selvakumar G.P., Ahmed M.E. et al. COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist. 2020; 26 (5-6): 402–414. DOI: 10.1177/1073858420941476.

12. Theoharides T.C. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. Biofactors. 2020; 46 (3): 306–308. DOI: 10.1002/biof.1633.

13. Kosanovic D., Luitel H., Dahal B.K. et al. Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis. Eur. Respir. J. 2015; 46 (4): 1084–1094. DOI: 10.1183/09031936.00018215.

14. Banin I.N., Budnevsky A.V., Grechkin V.I. et al. The experience of surfactant therapy in severe COVID-19 pneumonia: a case report. Int. J. Biomed. 2021; 11 (2): 177–180. DOI: 10.21103/Article11(2)_CR1.

15. Yaroshetsky A.I., Gritsan A.I., Avdeev S.N. et al. [Diagnostics and intensive therapy of acute respiratory distress syndrome (Clinical guidelines of the Federation of Anesthesiologists and Reanimatologists of Russia)]. Anesteziologiya i reanimatologiya. 2020; (2): 5–39. DOI: 10.17116/anaesthesiology20200215 (in Russian).

16. ARDS Definition Task Force, Ranieri V.M., Rubenfeld G.D. et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012; 307 (23): 2526–2533. DOI: 10.1001/jama.2012.5669.

17. Buchwalow I.B., Boecker W. Immunohistochemistry: basics and methods. Berlin: Springer; 2010.

18. Atiakshin D., Buchwalow I., Samoilova V., Tiemann M. Tryptase as a polyfunctional component of mast cells. Histochem. Cell Biol. 2018; 149 (5): 461–477. DOI: 10.1007/s00418-018-1659-8.

19. Atiakshin D., Buchwalow I., Tiemann M. Mast cell chymase: morphofunctional characteristics. Histochem. Cell Biol. 2019; 152 (4): 253–269. DOI: 10.1007/s00418-019-01803-6.

20. Shishkina V.V., Klochkova S.V., Alekseeva N.T. et al. [Tryptase profile of rat skin mast cell population during wound healing]. Zhurnal anatomii i gistopatologii. 2020; 9 (4): 84–89. DOI: 10.18499/22257357-2020-9-4-84-89 (in Russian).

21. Motta Junior J.D.S., Miggiolaro A.F.R.D.S., Nagashima S. et al. Mast cells in alveolar septa of COVID-19 patients: a pathogenic pathway that may link interstitial edema to immunothrombosis. Front. Immunol. 2020; 11: 574862. DOI: 10.3389/fimmu.2020.574862.

22. Zhou Z., Ren L., Zhang L. et al. Heightened Innate Immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020; 27 (6): 883–890.e2. DOI: 10.1016/j.chom.2020.04.017.

23. Gebremeskel S., Schanin J., Coyle K.M. et al. Mast cell and eosinophil activation are associated with COVID-19 and TLR-mediated viral inflammation: Implications for an Anti-Siglec-8 antibody. Front. Immunol. 2021; 12: 650331. DOI: 10.3389/fimmu.2021.650331.

24. Tan J., Anderson D.E., Rathore A.P.S. et al. Signatures of mast cell activation are associated with severe COVID-19. MedRxiv. 2021; 2021.05.31.21255594. DOI: 10.1101/2021.05.31.21255594.

25. Soria-Castro R., Meneses-Preza Y.G., Rodríguez-Lopez G.M. et al. Severe COVID-19 is marked by dysregulated serum levels of carboxypeptidase A3 and serotonin. J. Leukoc. Biol. 2021; 110 (3): 425–431. DOI: 10.1002/JLB.4HI0221-087R.

26. Afrin L.B. Presentation, diagnosis, and management of mast cell activation syndrome. In: Murray D.B., ed. Mast cells: Phenotypic features, biological functions and role in immunity. Hauppoge: Nova Science Publishers; 2013: 155–232. Available at: https://www.jillcarnahan.com/downloads/MCAS-Afrin.pdf [Accessed: July 10, 2022].

27. Vliagoftis H., Lacy P., Luy B. et al. Mast cell tryptase activates peripheral blood eosinophils to release granule-associated enzymes. Int. Arch. Allergy Immunol. 2004; 135 (3): 196–204. DOI: 10.1159/000081304.

28. Lippi G., Plebani M., Henry B.M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin. Chim. Acta. 2020; 506: 145–148. DOI: 10.1016/j.cca.2020.03.022.

29. Zhao X., Wang K., Zuo P. et al. Early decrease in blood platelet count is associated with poor prognosis in COVID-19 patients-indications for predictive, preventive, and personalized medical approach. EPMA J. 2020; 11 (2): 139–145. DOI: 10.1007/s13167-020-00208-z.